[Treatment of postmenopausal osteoporosis].
Prevention and treatment of osteoporosis consists of non-drug and drug therapy. This review of the topic will provide an overview of the approach to therapy of osteoporosis in postmenopausal women. In the past, estrogen replacement was considered a primary therapy for the prevention of postmenopausal osteoporosis. However, data from the Womeńs Health Initiative (WHI) revealed that estrogen-progestine therapy does not reduce the risk of coronary heart disease, and increases the risk of breast cancer, stroke, and venous thromboembolic events. As a result of these findings, other antiresorptive agents are now the drugs of choice for the prevention and treatment of osteoporosis in postmenopausal women.
Loza
E
E
Sección de Reumatología, Hospital de Navarra, Pamplona, 31008, Pamplona, Spain.
D002116:Calcitonin / Q000627:therapeutic use; D004032:Diet; D019587:Dietary Supplements; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000628:therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D004164:Diphosphonates; D010281:Parathyroid Hormone; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D002116:Calcitonin